Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database

Area of Science:

• Oncology
• Clinical Research
• Pharmacology

Background:

• Anaplastic Lymphoma Kinase (ALK)-rearranged advanced Non-Small Cell Lung Cancer (aNSCLC) accounts for 4% of NSCLC cases.
• Multiple ALK-inhibitors are available, but real-world data on treatment patterns and survival impact are limited.
• Understanding prognostic factors and treatment sequences is crucial for optimizing patient outcomes.

Purpose of the Study:

• To describe treatment patterns, survival outcomes, and prognostic factors in a large real-world cohort of ALK-positive aNSCLC patients.
• To evaluate the impact of initial and subsequent therapies on overall survival.
• To identify factors influencing survival in ALK-positive aNSCLC.

Main Methods:

• Retrospective observational cohort study using deidentified electronic health records from U.S. cancer clinics.
• Analysis of 739 patients diagnosed with ALK-positive aNSCLC between 2011 and 2020.
• Examination of over 168 distinct treatment sequences and associated survival data.

Main Results:

• Median overall survival for the cohort was 37 months.
• Positive prognostic factors included never-smoking history, younger age, academic treatment setting, and early diagnosis stage.
• Initial treatment with a second-generation ALK-inhibitor was associated with improved survival versus chemotherapy.
• Treatment utilization patterns evolved over the study period.

Conclusions:

• First-line treatment with a second-generation ALK-inhibitor significantly improves survival in ALK-positive aNSCLC compared to chemotherapy.
• Identified clinical prognostic factors provide valuable insights for patient management.
• This study affirms the practice of using second-generation ALK-inhibitors as initial therapy.